ProKidney signs agreement with Jefferies for up to $200 million at-the-market share offering
PROK•ProKidney entered an at-the-market sales agreement with Jefferies for up to $200 million of Class A common stock, subject to the shelf registration statement becoming effective. Jefferies may receive up to 3% of gross proceeds, and ProKidney is not obligated to sell shares.
1. Offering terms
ProKidney entered the agreement with Jefferies on October 29, 2026. The offering permits sales of up to $200 million in Class A common stock, subject to the shelf registration statement becoming effective. Jefferies will receive up to 3% of gross offering proceeds as compensation; ProKidney may suspend the offering at any time and has no obligation to sell shares.
